A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

Present or complication with other malignancies within 5 years.

Subjects are known to have genetic abnormalities with approved targeted drug therapy.

Cirrhosis, active hepatitis;

Cardio-cerebrovascular abnormalities;

Subjects with severe active infection within 4 weeks prior to initiation of study treatment; Or unexplained fever \>38.0 ℃ occurred during screening and before first administration;

Patients with active tuberculosis within 1 year prior to enrollment;

Immunodeficiency disease;

History of active autoimmune disease or autoimmune disease;

Preparing for or having previously received an organ transplant, or having received a hematopoietic stem cell transplant within 60 days prior to initial medication, or having a significant host transplant response;

Patients who required immunosuppressive, systemic, or absorbable topical hormone therapy for immunosuppressive purposes and continued use within two weeks prior to randomization

Severe infection of grade 4 or higher occurred within 1 year prior to initiation of study therapy;

Severe lung disease;

History of pituitary or adrenal dysfunction;

History of severe mental disorder;

History of drug abuse, alcoholism or drug use;

Participated in clinical trials of other drugs within 30 days;

History of live attenuated vaccine vaccination within 28 days prior to randomization or planned live attenuated vaccine vaccination during the study period;

Received Chinese patent drugs with anti-tumor indications specified in the National Medical Product Administration approved drug package inserts within 2 weeks prior to initiation of administration

Had major surgery within 4 weeks prior to initiation of medication;

Other severe, acute, or chronic medical conditions or laboratory abnormalities that, in the investigator's opinion, may increase the risks associated with study participation or may interfere with the interpretation of the study results, or are otherwise unsuitable for participation in the clinical study;

The compliance of patients to participate in this clinical study is estimated to be insufficient.

What this study is about